Ridgeway Therapeutics Inc

VIVUS Inc., based in Menlo Park, CA, is committed to improving patient quality of life by addressing the therapeutic needs of individuals with serious medical conditions and life-limiting diseases. With a portfolio that includes PANCREAZE for Exocrine Pancreatic Insufficiency (EPI), the company showcases its expertise in clinical development and commercialization of effective therapies. VIVUS focuses on managing chronic diseases, such as EPI, where patients experience deficiencies in pancreatic enzyme production, leading to severe health issues like malnutrition and weight loss. By providing innovative treatment options, VIVUS aims to enhance the lives of those affected by these debilitating conditions. Generated from the website

Alphalyse, located in Palo Alto, CA, specializes in mass spectrometry services that enhance the analysis and characterization of host cell proteins (HCP) in biopharmaceuticals. With over 20 years of experience and a proven track record of delivering over 10,800 reports, the company partners with biotech enterprises, contract manufacturing organizations, and pharmaceutical companies in North America and Europe. The Alphalyse team is dedicated to providing personalized advice and support to optimize the drug development process, ensuring that clients benefit from advanced analytical techniques without the need for extensive in-house training. Their GMP-compliant services include detailed risk assessments and extensive knowledge of product attributes, positioning Alphalyse as a trusted extension of their clients' teams. Generated from the website

Biomea Fusion, Inc., based in Redwood City, CA, is a clinical-stage biopharmaceutical company dedicated to revolutionizing medicine through the development of novel covalent small molecules aimed at curing serious and life-threatening diseases. The company has established a robust research and development engine that has produced multiple innovative drug programs currently in preclinical and clinical development. Focused on addressing key mechanisms of disease progression, Biomea's team is involved in all phases of drug discovery and development, including target selection, small molecule design, and clinical studies. Their commitment to creating highly selective targeted medicines positions them at the forefront of therapeutic innovation in diabetes and obesity treatment. Generated from the website